Therapeutic Efficacy of Risankizumab for Small-Intestinal Lesions in Crohn’s Disease: A Retrospective Study Using Double-Balloon Endoscopy

This study confirms the therapeutic efficacy of RZB for deep small-intestinal involvement in CD based on comprehensive DBE assessment. The results support the clinical utility of RZB in patients with refractory small-intestinal lesions, highlighting its potential to maintain 1 year disease control when ongoing mucosal inflammation is a concern. These findings underscore the importance of deep enteroscopic evaluation to optimize therapeutic strategies.